Safety, pharmacokinetics, and preliminary efficacy of BYON4413 in acute myeloid leukemia and myelodysplastic neoplasms.

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-507781-13-00

Acronym

BYON4413.001

Enrollment

Registered

2024-04-30

Start date

2024-05-24

Completion date

2025-09-30

Last updated

2025-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with relapsed/refractory acute myeloid leukemia or myelodysplastic neoplasms

None listed

Sex/Gender

All

Age

18 Years to No maximum

Belgium, Netherlands, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026